Previous studies examining clinical features of myeloid sarcoma.
| Total | De novo | Simultaneous haematological disorders | Previous haematological disorders | |
| Our study | 45 | 26 (6 AML, 1 MDS-MPN) | 7 (7 AML) | 12 (4 AML, 4 MDS, 3 MPN, 1 MDS-MPN-myelofibrosis) |
| Pileri et al11 | 92 | 25 (2 AML) | 32 (26 AML, 1 idiopathic myelofibrosis, 5 MDS) | 35 (12 AML, 14 MPN, 9 MDS) |
| Kawamoto et al34 | 131 | 35 | 37 (37 AML) | 59 (31 MDS-MPN-CML, 28 AML) |
| Al-Khateeb et al48 | 21 | 8 | 13 (1 CML-blastic phase, 12 AML) | |
| Chen et al49 | 20 | 1 | 19 (14 AML, 4 CML, 1 MDS with AML) | |
| Ullman et al36 | 63 | 23 (5AML) | 27 | 13 (10 MDS-MPN, 3 CML with blastic crisis) |
| Claerhout et al18 | 72 | 19 | 22 (15 AML, 2 MPN, 2 MDS, 3 MDS-MPN) | 31 (11 AML, 9 AML had arisen from MPN, 8 AML arisen from MDS, 3 AML arisen from MDS-MPN) |
| Wang and Li23 | 39 | 14 | 9 (8 AML, 1 CML) | 8 (7 AML, 1 MDS) |
| Zhou et al50 | 33 | 4 | 12 (12 AML) | 17 (14 AML, 1 JMML, 1 atypical CML, 1 MDS-MPN) |
AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; JMML, juvenil myelomonocytic leukaemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.